Evidence map›Paper›PMID 27528888›Full record

ArticleOxidative medicine and cellular longevity2016

Xanthine Oxidase-Derived ROS Display a Biphasic Effect on Endothelial Cells Adhesion and FAK Phosphorylation.

Meriem H Ben-Mahdi, Pham My-Chan Dang, Marie-Anne Gougerot-Pocidalo, Yvonne O'Dowd, Jamel El-Benna, Catherine Pasquier

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Potential ProbioticMicroorganisms · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Meriem H Ben-MahdiVeterinary National Superior School of Algiers, BP 161, Hacène Badi, El Harrach, 16200 Algiers, Algeria; INSERM-U1149, CNRS-ERL 8252, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Laboratoire d'Excellence Inflamex, DHU FIRE, Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Site Xavier Bichat, 75018 Paris, France.ORCID 0000-0003-4202-5364
Pham My-Chan DangINSERM-U1149, CNRS-ERL 8252, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Laboratoire d'Excellence Inflamex, DHU FIRE, Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Site Xavier Bichat, 75018 Paris, France.
Marie-Anne Gougerot-PocidaloINSERM-U1149, CNRS-ERL 8252, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Laboratoire d'Excellence Inflamex, DHU FIRE, Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Site Xavier Bichat, 75018 Paris, France.
Yvonne O'DowdINSERM-U1149, CNRS-ERL 8252, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Laboratoire d'Excellence Inflamex, DHU FIRE, Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Site Xavier Bichat, 75018 Paris, France.ORCID 0000-0002-0027-9131
Jamel El-BennaINSERM-U1149, CNRS-ERL 8252, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Laboratoire d'Excellence Inflamex, DHU FIRE, Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Site Xavier Bichat, 75018 Paris, France.ORCID 0000-0001-5733-216X
Catherine PasquierINSERM-U1149, CNRS-ERL 8252, Centre de Recherche sur l'Inflammation, 75018 Paris, France; Laboratoire d'Excellence Inflamex, DHU FIRE, Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Site Xavier Bichat, 75018 Paris, France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In pathological situations such as ischemia-reperfusion and acute respiratory distress syndrome, reactive oxygen species (ROS) are produced by different systems which are involved in endothelial cells injury, ultimately leading to severe organ dysfunctions. The aim of this work was to study the effect of ROS produced by hypoxanthine-xanthine oxidase (Hx-XO) on the adhesion of human umbilical vein endothelial cells (HUVEC) and on the signaling pathways involved. Results show that Hx-XO-derived ROS induced an increase in HUVEC adhesion in the early stages of the process (less than 30 min), followed by a decrease in adhesion in the later stages of the process. Interestingly, Hx-XO-derived ROS induced the same biphasic effect on the phosphorylation of the focal adhesion kinase (FAK), a nonreceptor tyrosine kinase critical for cell adhesion, but not on ERK1/2 phosphorylation. The biphasic effect was not seen with ERK1/2 where a decrease in phosphorylation only was observed. Wortmannin, a PI3-kinase inhibitor, inhibited ROS-induced cell adhesion and FAK phosphorylation. Orthovanadate, a protein tyrosine phosphatase inhibitor, and Resveratrol (Resv), an antioxidant agent, protected FAK and ERK1/2 from dephosphorylation and HUVEC from ROS-induced loss of adhesion. This study shows that ROS could have both stimulatory and inhibitory effects on HUVEC adhesion and FAK phosphorylation and suggests that PI3-kinase and tyrosine phosphatase control these effects.

Indexed as

AndrostadienesCell AdhesionFocal Adhesion Protein-Tyrosine KinasesHumansHuman Umbilical Vein Endothelial CellsHypoxanthineImmunoprecipitationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationReactive Oxygen SpeciesResveratrolStilbenesWortmanninAndrostadienesFocal Adhesion Protein-Tyrosine KinasesHypoxanthineMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsReactive Oxygen SpeciesResveratrolStilbenesWortmanninXanthine Oxidase

Identifiers

PMID27528888
PMCPMC4978831
OpenAlexW2491933458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.